At the time of writing, Adaptimmune Therapeutics Plc ADR [ADAP] stock is trading at $0.28, up 9.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ADAP shares have gain 18.93% over the last week, with a monthly amount drifted -2.54%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] stock has seen the most recent analyst activity on June 26, 2025, when Mizuho downgraded its rating to a Neutral but kept the price target unchanged to $0.50 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on July 30, 2024, and set its price target to $4. On May 30, 2024, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $3.15 on the stock. Bryan Garnier started tracking the stock assigning a Buy rating and suggested a price target of $3.60 on March 24, 2023. Guggenheim upgraded its rating to a Buy but $5 remained the price target by the analyst firm on January 03, 2023. Mizuho upgraded its rating to Buy for this stock on November 09, 2022, but kept the price target unchanged to $9. In a note dated May 28, 2021, Barclays initiated an Underweight rating and provided a target price of $4 on this stock.
For the past year, the stock price of Adaptimmune Therapeutics Plc ADR fluctuated between $0.20 and $1.48. Currently, Wall Street analysts expect the stock to reach $2.83 within the next 12 months. Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] shares were valued at $0.28 at the most recent close of the market. An investor can expect a potential return of 910.71% based on the average ADAP price forecast.
Analyzing the ADAP fundamentals
According to Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP], the company’s sales were 180.20M for trailing twelve months, which represents an 28.87% jump. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.36%, Pretax Profit Margin comes in at -0.38%, and Net Profit Margin reading is -0.39%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -1.86 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.62.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2605 points at the first support level, and at 0.2453 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2855, and for the 2nd resistance point, it is at 0.2953.
Ratios To Look Out For
It is important to note that Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] has a current ratio of 2.02. As well, the Quick Ratio is 1.79, while the Cash Ratio is 0.8. Considering the valuation of this stock, the price to sales ratio is 0.39.
Transactions by insiders
Recent insider trading involved Norry Elliot, Chief Medical Officer, that happened on Jan 17 ’25 when 5584.0 shares were sold. Chief Patient Supply Officer, Lunger John completed a deal on Jan 17 ’25 to sell 5584.0 shares. Meanwhile, Chief Operating Officer Bertrand William C JR sold 5584.0 shares on Jan 17 ’25.
